Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 1:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 12,737 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Male Clear all
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Pediatric Urology Recovery After Surgery Endeavor (PURSUE)

NCT03245242
View directory record Official record
Conditions
Urologic Surgical Procedures, Urinary Bladder, Neurogenic, Urinary Bladder Diseases
Interventions
Enhanced Recovery after Surgery, Historical usual surgical care
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
4 Years to 25 Years
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2026
U.S. locations
7
States / cities
Aurora, Colorado • Chicago, Illinois • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2025 · Synced Oct 23, 2026, 1:32 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Talazoparib and Axitinib for People With Previously Treated Advanced Kidney Cancer

NCT04337970
View directory record Official record
Conditions
Kidney Cancer, Renal Cell Carcinoma, Unresectable Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma
Interventions
Talazoparib, Axitinib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 23, 2026, 1:32 AM EDT
Enrolling by invitation Phase 2 Interventional

Isotretinoin vs hCG for Male Infertility Due to Low or Absent Sperm

NCT07481370
View directory record Official record
Conditions
Oligospermia, Azoospermia, Nonobstructive, Infertility
Interventions
isotretinoin, Human chorionic gonadotrophin (hCG)
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 50 Years · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 23, 2026, 1:32 AM EDT
Active, not recruiting No phase listed Observational

An Observational Registry Assessing the Impact of PYLARIFY® (Piflufolastat F18) PET in Patients With Prostate Cancer

NCT05712473
View directory record Official record
Conditions
Prostate Cancer
Interventions
PYLARIFY
Diagnostic Test
Lead sponsor
Lantheus Medical Imaging
Industry
Eligibility
21 Years and older · Male only
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
12
States / cities
Homewood, Alabama • Little Rock, Arkansas • Fresno, California + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 23, 2026, 1:32 AM EDT
Recruiting Phase 3 Interventional

A Phase III Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With CKD Stage 3b and 4 (BalanceD-CKD)

NCT07624305
View directory record Official record
Conditions
Renal Insufficiency, Chronic
Interventions
Balcinrenone/dapagliflozin, Dapagliflozin, Placebo matching Dapagliflozin, Placebo matching balcinrenone/dapagliflozin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 99 Years
Enrollment
2,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
68
States / cities
Huntsville, Alabama • Surprise, Arizona • Tempe, Arizona + 63 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 23, 2026, 1:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Impact of Behavioral Treatment of Insomnia on Nighttime Urine Production

NCT03883724
View directory record Official record
Conditions
Sleep Fragmentation, Poor Quality Sleep, Nocturia, Nocturnal Enuresis
Interventions
Brief behavioral treatment of insomnia (BBTI), Information-only control (IC)
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
65 Years and older
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 22, 2022 · Synced Oct 23, 2026, 1:32 AM EDT
Completed Phase 3 Interventional Results available

S9921, Hormone Therapy With or Without Mitoxantrone and Prednisone in Patients Who Have Undergone Radical Prostatectomy for Prostate Cancer

NCT00004124
View directory record Official record
Conditions
Prostate Cancer
Interventions
bicalutamide, goserelin, mitoxantrone hydrochloride, prednisone
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 120 Years · Male only
Enrollment
983 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2018
U.S. locations
234
States / cities
Anchorage, Alaska • Glendale, Arizona • Phoenix, Arizona + 157 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2022 · Synced Oct 23, 2026, 1:32 AM EDT
Active, not recruiting No phase listed Observational

AFFINITY BEYOND: Anti-AAV8 Antibody Assessment Study of Males With DMD

NCT05683379
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
AAV8 DetectCDx
Diagnostic Test
Lead sponsor
REGENXBIO Inc.
Industry
Eligibility
0 Years to 25 Years · Male only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 23, 2026, 1:32 AM EDT
Active, not recruiting Phase 3 Interventional

Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN)

NCT05248646
View directory record Official record
Conditions
Immunoglobulin A Nephropathy
Interventions
Sibeprenlimab 400 mg, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
54
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 39 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 23, 2026, 1:32 AM EDT
Completed Phase 1 Interventional

Pembrolizumab and Docetaxel or Gemcitabine Hydrochloride in Treating Patients Urothelial Cancer

NCT02437370
View directory record Official record
Conditions
Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter, Recurrent Bladder Carcinoma, Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter, Regional Urothelial Carcinoma of the Renal Pelvis and Ureter, Stage III Bladder Urothelial Carcinoma, Stage III Urethral Cancer, Stage IV Bladder Urothelial Carcinoma, Stage IV Urethral Cancer, Urethral Urothelial Carcinoma
Interventions
Pembrolizumab, Docetaxel, Gemcitabine Hydrochloride
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Oct 18, 2022 · Synced Oct 23, 2026, 1:32 AM EDT
Completed No phase listed Observational

Biomechanical Assessment of Level Gait in Patient's Status Post Bladder Exstrophy

NCT00863070
View directory record Official record
Conditions
Bladder Exstrophy
Interventions
Not listed
Lead sponsor
Connecticut Children's Medical Center
Other
Eligibility
4 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
2
States / cities
Farmington, Connecticut • Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 20, 2017 · Synced Oct 23, 2026, 1:32 AM EDT
Completed Phase 1 Interventional

J591 in Patients With Advanced Prostate Cancer and Unfavorable Circulating Tumor Cell Counts

NCT02552394
View directory record Official record
Conditions
Prostate Cancer
Interventions
huJ591
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 6, 2023 · Synced Oct 23, 2026, 1:32 AM EDT
Completed Phase 2 Interventional Results available

A Study to Test BI 764198 in People With a Type of Kidney Disease Called Focal Segmental Glomerulosclerosis

NCT05213624
View directory record Official record
Conditions
Kidney Disease, Chronic
Interventions
BI 764198, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
20
States / cities
Huntsville, Alabama • San Francisco, California • South Gate, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Oct 23, 2026, 1:32 AM EDT
Terminated Phase 3 Interventional Results available

Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder

NCT01310803
View directory record Official record
Conditions
Carcinoma in Situ, Transitional Cell Carcinoma, Non-muscle Invasive Bladder Cancer
Interventions
VALSTAR - Maintenance Therapy, No Maintenance treatment ( Standard of Care)
Drug · Other
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
6
States / cities
Phoenix, Arizona • Denver, Colorado • Cumberland, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2017 · Synced Oct 23, 2026, 1:32 AM EDT
Not listed Not applicable Interventional

Does Bladder Instillation Reduce Time to Discharge After Sling Surgery

NCT02277288
View directory record Official record
Conditions
Stress Urinary Incontinence
Interventions
Filled bladder arm
Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2025
U.S. locations
1
States / cities
Beverly Hills, California
Source: ClinicalTrials.gov public record
Updated Jul 18, 2018 · Synced Oct 23, 2026, 1:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of Eleclazine in Adults With Normal and Impaired Renal Function

NCT02441829
View directory record Official record
Conditions
Long QT Syndrome
Interventions
Eleclazine
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
5
States / cities
DeLand, Florida • Miami, Florida • Orlando, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2015 · Synced Oct 23, 2026, 1:32 AM EDT
Completed Phase 1 Interventional

Monoclonal Antibody ABX-EGF in Treating Patients With Renal (Kidney), Prostate, Pancreatic, Non-Small Cell Lung, Colon or Rectal, Esophageal, or Gastroesophageal Junction Cancer

NCT00004879
View directory record Official record
Conditions
Colorectal Cancer, Esophageal Cancer, Kidney Cancer, Lung Cancer, Pancreatic Cancer, Prostate Cancer
Interventions
panitumumab
Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
2
States / cities
Los Angeles, California • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 8, 2013 · Synced Oct 23, 2026, 1:32 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers

NCT02643303
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma, Breast Cancer, Sarcoma, Merkel Cell Carcinoma, Cutaneous T-Cell Lymphoma, Melanoma, Renal Cancer, Bladder Cancer, Prostate Cancer, Testicular Cancer, Solid Tumor
Interventions
Durvalumab, Tremelimumab, Poly-ICLC
Drug
Lead sponsor
Ludwig Institute for Cancer Research
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
7
States / cities
Atlanta, Georgia • Lebanon, New Hampshire • Buffalo, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2022 · Synced Oct 23, 2026, 1:32 AM EDT
Completed Not applicable Interventional Results available

Optimizing Veteran-Centered Prostate Cancer Survivorship Care

NCT01900561
View directory record Official record
Conditions
Prostate Cancer
Interventions
Interactive Voice Response Symptom Management, Tailored Newsletters
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
40 Years to 80 Years · Male only
Enrollment
556 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
4
States / cities
Ann Arbor, Michigan • St Louis, Missouri • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated May 7, 2019 · Synced Oct 23, 2026, 1:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Technology-Enhanced Acceleration of Germline Evaluation for Therapy, TARGET Study

NCT04447703
View directory record Official record
Conditions
Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8
Interventions
Interview, Internet-Based Intervention, Survey Administration, Genetic Counseling, Genetic Testing
Other · Genetic
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
346 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
5
States / cities
New York, New York • Syracuse, New York • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Oct 23, 2026, 1:32 AM EDT
Not listed Phase 2 Interventional

A Phase II Study of Lonsurf (TAS-102) in Metastatic Platinum and Checkpoint Inhibitor-resistant Bladder Cancer

NCT03762161
View directory record Official record
Conditions
Bladder Cancer
Interventions
TAS 102
Drug
Lead sponsor
Rahul Parikh
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
2
States / cities
Fairway, Kansas • Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 10, 2022 · Synced Oct 23, 2026, 1:32 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma

NCT02811861
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Lenvatinib, Everolimus, Pembrolizumab, Sunitinib
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,069 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
35
States / cities
Stanford, California • Boca Raton, Florida • Fort Myers, Florida + 29 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Oct 23, 2026, 1:32 AM EDT
Not listed Not applicable Interventional

Painless Laser Therapy for Overactive Bladder

NCT01569061
View directory record Official record
Conditions
Overactive Bladder
Interventions
LCT-1000TM (Manufacturer: LiteCure)
Device
Lead sponsor
Zipper Urogynecology Associates
Other
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Melbourne, Florida
Source: ClinicalTrials.gov public record
Updated Apr 2, 2012 · Synced Oct 23, 2026, 1:32 AM EDT
Withdrawn Phase 1 Interventional

RO4929097 in Children With Relapsed/Refractory Solid or CNS Tumors, Lymphoma, or T-Cell Leukemia

NCT01236586
View directory record Official record
Conditions
Lymphoma, Brain Neoplasms, Sarcoma, Osteosarcoma, Wilm's Tumor
Interventions
RO4929097, Dexamethasone
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 21 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Bethesda, Maryland • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 23, 2026, 1:32 AM EDT